´ëÇÑ°ñ´Ù°øÁõÇÐȸ Ãá°èExpert Meeting : 2021-04-04±³À°ÀÏÀÚ : 2021-04-04
±³À°Àå¼Ò : ¼¿ïµå·¡°ï½ÃƼȣÅÚ 5Ãþ 3·ë
±³À°ÁÖÁ¦ :
´ëÇÑ°ñ´Ù°øÁõÇÐȸ Ãá°èExpert Meeting ÁÖÃÖ±â°ü : ´ëÇÑ°ñ´Ù°øÁõÇÐȸ
´ã´çÀÚ : ¿À¼ºÈñ
¿¬¶ôó : 02-777-9896
À̸ÞÀÏ :
work@koreanosteoporosis.or.kr ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, Á¤½Å°Ç°ÀÇÇаú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, À̺ñÀÎÈÄ°ú, ÇǺΰú, ¿µ»óÀÇÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, ÀçÈ°ÀÇÇаú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаúÀÇ»çÇÐ, ÀÇÇб³À°, ÀÇ·áÁ¤Ã¥,
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 7 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 80,000¿ø
ºñ°í Á¤È¸¿ø:ÀüÀÓÀÇ5¸¸¿ø/ °³¿øÀÇ ºÀÁ÷ÀÇ 6¸¸¿ø ºñȸ¿ø : ÀüÀÓÀÇ 6¸¸¿ø/ °³¿øÀÇ ºÀÁ÷ÀÇ 8¸¸¿ø Àü°øÀÇ, °£È£»ç : 2¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04¿ù 04ÀÏ ¼¿ïµå·¡°ï½ÃƼ 5Ãþ 3·ë 09:00~09:20 Role of macrophages in bone metabolism and fracture repair À̼ö¿µ(ÀÌÈ´ëÇб³)
±³À°½Ã°£ 04¿ù 04ÀÏ ¼¿ïµå·¡°ï½ÃƼ 5Ãþ 3·ë 09:20~09:40 Role of mechanical loading for bone anabolic response °íÁ¤ÅÂ(Àü³²Ä¡´ë)
±³À°½Ã°£ 04¿ù 04ÀÏ ¼¿ïµå·¡°ï½ÃƼ 5Ãþ 3·ë 09:40~10:00 Bilology of bone metastasis ¹Ú¿ëÁÖ(Àü³²´ëÇб³)
Åä·Ð 04¿ù 04ÀÏ ¼¿ïµå·¡°ï½ÃƼ 5Ãþ 3·ë 10:00~10:20 Q & A ()
ÈÞ½Ä 04¿ù 04ÀÏ ¼¿ïµå·¡°ï½ÃƼ 5Ãþ 3·ë 10:20~10:40 Coffee Break ()
±³À°½Ã°£ 04¿ù 04ÀÏ ¼¿ïµå·¡°ï½ÃƼ 5Ãþ 3·ë 10:40~11:00 Osteoporosis and sarcopenia: two diseases or one? ¿øÀå¿ø(°æÈñÀÇ´ë)
±³À°½Ã°£ 04¿ù 04ÀÏ ¼¿ïµå·¡°ï½ÃƼ 5Ãþ 3·ë 11:00~11:20 Which is better for fracture prevention, osteoporosis or sarcopenia? Á¶ÇöÈñ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 04¿ù 04ÀÏ ¼¿ïµå·¡°ï½ÃƼ 5Ãþ 3·ë 11:20~11:40 Modulation of intramuscular Vitamin D receptor (VDR) expression for the treatment of sarcopenia ±è°æ¼ö(°æÈñ´ë ÀÓ»ó¾à¸®ÇÐ)
Åä·Ð 04¿ù 04ÀÏ ¼¿ïµå·¡°ï½ÃƼ 5Ãþ 3·ë 11:40~12:00 Q & A ()
±³À°½Ã°£ 04¿ù 04ÀÏ ¼¿ïµå·¡°ï½ÃƼ 5Ãþ 3·ë 12:00~12:30 New paradigm of treating osteoporosis patients ÃÖÇѼ®(µ¿±¹ÀÇ´ë)
±³À°½Ã°£ 04¿ù 04ÀÏ ¼¿ïµå·¡°ï½ÃƼ 5Ãþ 3·ë 12:30~13:10 ½Ä»ç½Ã°£ ()
±³À°½Ã°£ 04¿ù 04ÀÏ ¼¿ïµå·¡°ï½ÃƼ 5Ãþ 3·ë 13:10~13:30 °ñÀýÀ» µ¿¹ÝÇÑ °ñ´Ù°øÁõ Áø·áÁöħ À̵¿¿Á(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 04¿ù 04ÀÏ ¼¿ïµå·¡°ï½ÃƼ 5Ãþ 3·ë 13:30~13:50 MRONJ °¡À̵å¶óÀÎ ÃÖ¿ëÁØ(¾ÆÁÖÀÇ´ë)
Åä·Ð 04¿ù 04ÀÏ ¼¿ïµå·¡°ï½ÃƼ 5Ãþ 3·ë 13:50~14:00 Q & A ()
±³À°½Ã°£ 04¿ù 04ÀÏ ¼¿ïµå·¡°ï½ÃƼ 5Ãþ 3·ë 14:00~14:20 Characteristics of each bone forming agent: teriparatide, abaloparatide and romososumab ¹Ú¼¼ÁØ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 04¿ù 04ÀÏ ¼¿ïµå·¡°ï½ÃƼ 5Ãþ 3·ë 14:20~14:40 Current status of bone forming therapies for the management of osteoporosis ±è»ó¹Î(°í·ÁÀÇ´ë)
Åä·Ð 04¿ù 04ÀÏ ¼¿ïµå·¡°ï½ÃƼ 5Ãþ 3·ë 14:40~14:50 Q & A ()
ÈÞ½Ä 04¿ù 04ÀÏ ¼¿ïµå·¡°ï½ÃƼ 5Ãþ 3·ë 14:55~15:10 Coffee Break ()
±³À°½Ã°£ 04¿ù 04ÀÏ ¼¿ïµå·¡°ï½ÃƼ 5Ãþ 3·ë 15:10~15:25 Fracture prevention in osteopenia patients ¿À¹üÁ¶(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04¿ù 04ÀÏ ¼¿ïµå·¡°ï½ÃƼ 5Ãþ 3·ë 15:25~15:40 Role of bisphosphonate in long-term osteoporosis treatment ¹ÚÀç¹Î(¿¬¼¼ÀÇ´ë)
Åä·Ð 04¿ù 04ÀÏ ¼¿ïµå·¡°ï½ÃƼ 5Ãþ 3·ë 15:40~15:50 Q & A ()
±³À°½Ã°£ 04¿ù 04ÀÏ ¼¿ïµå·¡°ï½ÃƼ 5Ãþ 3·ë 15:50~16:10 Calcium metabolism and vitamin D À̽ÃÈÆ(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 04¿ù 04ÀÏ ¼¿ïµå·¡°ï½ÃƼ 5Ãþ 3·ë 16:10~16:30 Management of osteoporosis and hip fragility fracture ±è±¤±Õ(°Ç¾çÀÇ´ë)
Åä·Ð 04¿ù 04ÀÏ ¼¿ïµå·¡°ï½ÃƼ 5Ãþ 3·ë 16:30~16:40 Q & A ()